Literature DB >> 677642

Retinal vascular occlusions and their treatment with low molecular weight dextran and vasodilators: report of six years' experience.

G M Gombos.   

Abstract

Fifty-two cases of retinal vascular occlusions were treated with retrobulbar injection of lidocaine (Xylocaine) and acethylcholine and systemic administration of low molecular weight dextran and papaverine hydrochloride. Twenty-eight patients had arterial occlusion while 24 patients suffered from venous occlusion. Improvement in vision was observed in 13 eyes (46%) with arterial occlusion. Sixteen patients (66%) with venous occlusion showed improvement in vision. Only 9 cases (17.3%) recovered completely (3 arterial occlusion and 6 venous occlusion). Good results were achieved only if treatment was started shortly after the onset of the disease. Systemic side effects of low molecular weight dextran were observed in 6 cases, all of which were excluded from the present study. Despite the relatively good results obtained with the use of low molecular dextran combined with papaverine hydrochloride in the treatment of retinal vascular occlusions, this treatment cannot be considered a revolutionary breakthrough.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 677642

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  3 in total

1.  Visual prognosis following treatment of acute central retinal artery obstruction.

Authors:  J J Augsburger; L E Magargal
Journal:  Br J Ophthalmol       Date:  1980-12       Impact factor: 4.638

2.  Successful treatment of central retinal artery thromboembolism with ocular massage and intravenous acetazolamide.

Authors:  Oliver Duxbury; Pervinder Bhogal; Geoffrey Cloud; Jeremy Madigan
Journal:  BMJ Case Rep       Date:  2014-12-05

3.  Central retinal artery occlusion due to infective endocarditis.

Authors:  Nikolaos G Ziakas; Sokratis Kotsidis; Antonios Ziakas
Journal:  Int Ophthalmol       Date:  2013-04-20       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.